Advanced Therapies Europe is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market. By bringing these two groups together, new partnerships can be forged to solidify Europe as a hub for cell and gene therapy.

 

 

 

 

 

  • Presentations & Posters

  • Venue

  • Discover More

CASE STUDY: SCALABLE PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRAL VECTORS 

 

Wednesday September 1, 2022 at 14:00 GMT

Speakers

  • Emmanuelle Cameau

    Strategic Technology Partnership Leader – Cell & Gene Therapy, Pall Corporation

 
Location: Royal Lancaster London
 
City, State & Country: London, UK

 

 

 

 

Manufacturing for Commercialization 


With continued clinical success and increased investment, gene therapy companies are looking toward manufacturing and commercialization of their lead therapies. The majority of gene therapies in clinical trials (92%) utilize viral vectors to carry the therapeutic gene into the target cells2. The most common method of making virus involves transfecting mammalian cells with one or more plasmid DNA to generate the viral vector. Once produced and harvested, the vector is then clarified, concentrated, purified, sterile filtered, quality tested, and stored for use either ex vivo or in vivo depending on the therapy and the virus type being used. Read More…

 

 

 

 

More Biotech Events
Join us at a location near you to meet our experts and product specialists, and learn out how the latest technical innovations can improve both the efficiency and quality of your processes at all scales.
October 2022
Congrès international A3P

Espace Bellevue, Biarritz

October 2022
Farmaforum 2022

Ifema, Madrid